Agape ATP (NASDAQ:ATPC – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agape ATP in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Read Our Latest Analysis on Agape ATP
Agape ATP Price Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in Agape ATP stock. Citadel Advisors LLC boosted its stake in shares of Agape ATP Corporation (NASDAQ:ATPC – Free Report) by 95.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,130 shares of the company’s stock after acquiring an additional 31,849 shares during the quarter. Citadel Advisors LLC owned about 0.13% of Agape ATP worth $82,000 as of its most recent SEC filing. 0.01% of the stock is currently owned by institutional investors and hedge funds.
Agape ATP Company Profile
Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names. The company's products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1-Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement.
Read More
Receive News & Ratings for Agape ATP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agape ATP and related companies with MarketBeat.com's FREE daily email newsletter.
